Gyre Therapeutics Income Statement Analysis

Revenue, earnings, and profit margins in millions USD

Scroll to see more
Gyre Therapeutics, Inc. income statement - Annual data in millions USD
BreakdownFY 2024FY 2023FY 2022FY 2021FY 2020FY 2019FY 2018
Period EndingDec 2024Dec 2023Dec 2022Dec 2021Dec 2020Dec 2019Dec 2018
Revenue & Gross Profit
Revenue105.76113.450.7989.5920.950.000.01
Cost of Revenue3.884.640.804.026.060.000.00
Gross Profit101.87108.810.0085.5714.890.000.00
Operating Expenses
Research & Development12.0213.7848.437.2552.9843.8621.47
Selling, General & Administrative73.6275.8217.3748.3316.1813.4212.35
Operating Expenses85.6489.60-65.7955.4378.32-57.2833.83
Operating Income16.23-67.23-65.8030.13-57.37-57.28-33.82
Other Income/Expense
Interest Income1.551.040.730.380.000.002.23
Interest Expense0.000.000.040.120.000.000.00
Other Income/Expense6.9514.12-57.19-0.790.09-0.011.54
Income
Income Before Tax23.22-76.97-7.8929.60-57.37-57.28-30.06
Income Tax Expense5.328.520.356.170.000.000.00
Net Income12.09-92.93-8.2423.44-56.24-55.18-30.06
Net Income - Continuous Operations17.90-85.484.3123.440.000.000.00
Net Income - Discontinued Operations0.000.000.000.000.000.000.00
EBITDA17.82-76.90-7.6631.66-57.23-57.13-33.67
EBIT16.23-78.01-7.8929.73-57.37-57.28-33.82
Depreciation & Amortization1.591.001.131.930.000.000.00
Earnings Per Share
Basic EPS--1.00---44.00--3.00
Diluted EPS--1.00---44.00-69.00-3.00
Basic Shares Outstanding85.0965.8331.5576.581.280.8011.21
Diluted Shares Outstanding102.2965.8331.5576.581.280.8011.21